QuidelOrtho Corp (QDEL)
QuidelOrtho Corp (QDEL) from its SEC filings: 2025 revenue $2.7 billion (-2% vs the year before), net margin -42%, free cash flow -$83.0 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | In Vitro & In Vivo Diagnostic Substances |
| Revenue (2025) | $2.7 billion |
| Revenue growth | -2% |
| Net income | -$1.1 billion |
| Net margin | -41.5% |
| Free cash flow | -$83.0 million |
| Diluted EPS | $-16.69 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +3% |
| Cash | $123.4 million |
| Long-term debt | $2.7 billion |
| Share count, 1 year | +1% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.